Vivan Therapeutics is among 78 companies selected for a grant from the EIC

20 Dec 2022

Vivan Therapeutics, Granatus' portfolio company, is among 78 companies selected for funding support in the form of a grant from the European Innovation Council (EIC).

The funds of €2.5m will support them for the commercialisation of TuMatch for colorectal cancer.

This great opportunity will allow Vivan Therapeutics to work with premier cancer institutes in Europe and generate the data required for approval and reimbursement.

More information is here >>